The p53 transcription factor is the most commonly altered gene in cancers. P53 also has two homologues called p63 and p73, which are rarely altered in cancers despite regulating many of the same target genes. Recently, as the potential of the immune system for fighting cancers has become apparent, p53 has been recognised as a critical regulator of immune processes.
Here we have investigated the role of p63 and p73 in this context, and report that they too, modify important aspects of cancer immunology. Moreover, they may have direct relevance to how inherited genetic features alter rates of cancer progression and our response to emerging immunotherapies.
|Date||Tuesday, 8 June 2021|
|Time||12:00pm - 1:00pm|
|Event Category||Health Sciences|
|Location||Biochemistry Seminar Room G.13 (BIG13), Dunedin|
|Contact Name||Department of Biochemistry|